Published in J Immunol on November 15, 2003
Viral antigen and extensive division maintain virus-specific CD8 T cells during chronic infection. J Exp Med (2007) 3.05
Inefficient cytotoxic T lymphocyte-mediated killing of HIV-1-infected cells in vivo. PLoS Biol (2006) 2.81
Molecular and cellular insights into T cell exhaustion. Nat Rev Immunol (2015) 2.74
Human immunodeficiency virus type 1 clade B superinfection: evidence for differential immune containment of distinct clade B strains. J Virol (2005) 1.77
Constraints on HIV-1 evolution and immunodominance revealed in monozygotic adult twins infected with the same virus. J Exp Med (2006) 1.72
Overcoming T cell exhaustion in infection and cancer. Trends Immunol (2015) 1.72
HIV-specific CD8 T cells express low levels of IL-7Ralpha: implications for HIV-specific T cell memory. Virology (2006) 1.54
Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection. J Virol (2005) 1.41
Evolution of human immunodeficiency virus type 1 cytotoxic T-lymphocyte epitopes: fitness-balanced escape. J Virol (2007) 1.35
Elite controllers with low to absent effector CD8+ T cell responses maintain highly functional, broadly directed central memory responses. J Virol (2012) 1.29
Limited sequence evolution within persistently targeted CD8 epitopes in chronic human immunodeficiency virus type 1 infection. J Virol (2005) 1.29
Dynamics of viral evolution and CTL responses in HIV-1 infection. PLoS One (2011) 1.21
Telomerase activity of HIV-1-specific CD8+ T cells: constitutive up-regulation in controllers and selective increase by blockade of PD ligand 1 in progressors. Blood (2008) 1.20
CD4+ T cell depletion in human immunodeficiency virus (HIV) infection: role of apoptosis. Viruses (2011) 1.07
Impact of select immunologic and virologic biomarkers on CD4 cell count decrease in patients with chronic HIV-1 subtype C infection: results from Sinikithemba Cohort, Durban, South Africa. Clin Infect Dis (2009) 1.02
Increasing CTL targeting of conserved sequences during early HIV-1 infection is correlated to decreasing viremia. AIDS Res Hum Retroviruses (2010) 1.02
Early HLA-B*57-restricted CD8+ T lymphocyte responses predict HIV-1 disease progression. J Virol (2012) 0.98
Structured observations reveal slow HIV-1 CTL escape. PLoS Genet (2015) 0.88
Quantifying the impact of human immunodeficiency virus-1 escape from cytotoxic T-lymphocytes. PLoS Comput Biol (2010) 0.88
Can non-lytic CD8+ T cells drive HIV-1 escape? PLoS Pathog (2013) 0.87
Primary human immunodeficiency virus type 1 (HIV-1) infection during HIV-1 Gag vaccination. J Virol (2008) 0.86
The evolutionary selective advantage of HIV-1 escape variants and the contribution of escape to the HLA-associated risk of AIDS progression. PLoS One (2008) 0.83
Partial escape of HIV-1 from cytotoxic T lymphocytes during chronic infection. J Virol (2012) 0.79
Predicting the impact of blocking human immunodeficiency virus type 1 Nef in vivo. J Virol (2008) 0.79
CD4+ T cell targeting of human immunodeficiency virus type 1 (HIV-1) peptide sequences present in vivo during chronic, progressive HIV-1 disease. Virology (2006) 0.77
Selection and accumulation of an HIV-1 escape mutant by three types of HIV-1-specific cytotoxic T lymphocytes recognizing wild-type and/or escape mutant epitopes. J Virol (2011) 0.76
Epitope shifting of gp90-specific cellular immune responses in EIAV-infected ponies. Vet Immunol Immunopathol (2014) 0.75
HIV-1 Epitope Variability Is Associated With T Cell Receptor Repertoire Instability and Breadth. J Virol (2017) 0.75
The major genetic determinants of HIV-1 control affect HLA class I peptide presentation. Science (2010) 9.61
Diversity considerations in HIV-1 vaccine selection. Science (2002) 9.60
Dominant influence of HLA-B in mediating the potential co-evolution of HIV and HLA. Nature (2004) 9.53
HIV preferentially infects HIV-specific CD4+ T cells. Nature (2002) 9.28
Comprehensive cross-clade neutralization analysis of a panel of anti-human immunodeficiency virus type 1 monoclonal antibodies. J Virol (2004) 8.99
Structure of a V3-containing HIV-1 gp120 core. Science (2005) 7.69
Reversion of CTL escape-variant immunodeficiency viruses in vivo. Nat Med (2004) 6.33
Public health. A sound rationale needed for phase III HIV-1 vaccine trials. Science (2004) 5.31
Direct evidence of extensive diversity of HIV-1 in Kinshasa by 1960. Nature (2008) 5.05
Propagation and dissemination of infection after vaginal transmission of simian immunodeficiency virus. J Virol (2005) 4.61
Founder effects in the assessment of HIV polymorphisms and HLA allele associations. Science (2007) 4.60
Advantage of rare HLA supertype in HIV disease progression. Nat Med (2003) 4.08
LXR signaling couples sterol metabolism to proliferation in the acquired immune response. Cell (2008) 4.02
Tracking global patterns of N-linked glycosylation site variation in highly variable viral glycoproteins: HIV, SIV, and HCV envelopes and influenza hemagglutinin. Glycobiology (2004) 3.98
T cell receptor recognition motifs govern immune escape patterns in acute SIV infection. Immunity (2004) 3.69
Transmission and accumulation of CTL escape variants drive negative associations between HIV polymorphisms and HLA. J Exp Med (2005) 3.68
Gag-specific CD8+ T lymphocytes recognize infected cells before AIDS-virus integration and viral protein expression. J Immunol (2007) 3.59
Mosaic HIV-1 vaccines expand the breadth and depth of cellular immune responses in rhesus monkeys. Nat Med (2010) 3.44
Quantitative deep sequencing reveals dynamic HIV-1 escape and large population shifts during CCR5 antagonist therapy in vivo. PLoS One (2009) 3.40
Influence of HLA-C expression level on HIV control. Science (2013) 3.27
Collagen deposition in HIV-1 infected lymphatic tissues and T cell homeostasis. J Clin Invest (2002) 2.82
Phenotypic properties of transmitted founder HIV-1. Proc Natl Acad Sci U S A (2013) 2.75
Biomarkers of microbial translocation and macrophage activation: association with progression of subclinical atherosclerosis in HIV-1 infection. J Infect Dis (2012) 2.64
Design and pre-clinical evaluation of a universal HIV-1 vaccine. PLoS One (2007) 2.61
Enhanced detection of human immunodeficiency virus type 1-specific T-cell responses to highly variable regions by using peptides based on autologous virus sequences. J Virol (2003) 2.53
Homeostasis of the naive CD4+ T cell compartment during aging. J Immunol (2008) 2.48
Increased CCR5 affinity and reduced CCR5/CD4 dependence of a neurovirulent primary human immunodeficiency virus type 1 isolate. J Virol (2002) 2.43
Use of a small molecule CCR5 inhibitor in macaques to treat simian immunodeficiency virus infection or prevent simian-human immunodeficiency virus infection. J Exp Med (2003) 2.37
Hydrodynamic stretching of single cells for large population mechanical phenotyping. Proc Natl Acad Sci U S A (2012) 2.37
Differential microRNA regulation of HLA-C expression and its association with HIV control. Nature (2011) 2.36
Optimization of methods to assess human mucosal T-cell responses to HIV infection. J Immunol Methods (2003) 2.32
A jumping profile Hidden Markov Model and applications to recombination sites in HIV and HCV genomes. BMC Bioinformatics (2006) 2.25
HIV sequence databases. AIDS Rev (2003) 2.20
Cross-clade detection of HIV-1-specific cytotoxic T lymphocytes does not reflect cross-clade antiviral activity. J Infect Dis (2008) 2.18
HIV evolution in early infection: selection pressures, patterns of insertion and deletion, and the impact of APOBEC. PLoS Pathog (2009) 2.15
Retrocyclin: a primate peptide that protects cells from infection by T- and M-tropic strains of HIV-1. Proc Natl Acad Sci U S A (2002) 2.14
Case of yellow fever vaccine--associated viscerotropic disease with prolonged viremia, robust adaptive immune responses, and polymorphisms in CCR5 and RANTES genes. J Infect Dis (2008) 2.14
The HIV Env variant N283 enhances macrophage tropism and is associated with brain infection and dementia. Proc Natl Acad Sci U S A (2006) 2.13
Genetic and functional analysis of full-length human immunodeficiency virus type 1 env genes derived from brain and blood of patients with AIDS. J Virol (2003) 2.07
Nef interference with HIV-1-specific CTL antiviral activity is epitope specific. Blood (2006) 1.91
HIV-1 Nef is preferentially recognized by CD8 T cells in primary HIV-1 infection despite a relatively high degree of genetic diversity. AIDS (2004) 1.89
Gene therapy for adenosine deaminase-deficient severe combined immune deficiency: clinical comparison of retroviral vectors and treatment plans. Blood (2012) 1.85
HLA-B63 presents HLA-B57/B58-restricted cytotoxic T-lymphocyte epitopes and is associated with low human immunodeficiency virus load. J Virol (2005) 1.76
Definition of the viral targets of protective HIV-1-specific T cell responses. J Transl Med (2011) 1.73
The role of recombination in the emergence of a complex and dynamic HIV epidemic. Retrovirology (2010) 1.69
Macrophage entry mediated by HIV Envs from brain and lymphoid tissues is determined by the capacity to use low CD4 levels and overall efficiency of fusion. Virology (2006) 1.66
Analysis of V2 antibody responses induced in vaccinees in the ALVAC/AIDSVAX HIV-1 vaccine efficacy trial. PLoS One (2013) 1.65
HIV-1 vaccine development after STEP. Annu Rev Med (2010) 1.64
jpHMM: improving the reliability of recombination prediction in HIV-1. Nucleic Acids Res (2009) 1.61
Role of maternal autologous neutralizing antibody in selective perinatal transmission of human immunodeficiency virus type 1 escape variants. J Virol (2006) 1.59
jpHMM at GOBICS: a web server to detect genomic recombinations in HIV-1. Nucleic Acids Res (2006) 1.58
Recurrent signature patterns in HIV-1 B clade envelope glycoproteins associated with either early or chronic infections. PLoS Pathog (2011) 1.57
Sensitivity and specificity of the ViroSeq human immunodeficiency virus type 1 (HIV-1) genotyping system for detection of HIV-1 drug resistance mutations by use of an ABI PRISM 3100 genetic analyzer. J Clin Microbiol (2005) 1.57
Expanded breadth of the T-cell response to mosaic human immunodeficiency virus type 1 envelope DNA vaccination. J Virol (2008) 1.51
Genetic signatures in the envelope glycoproteins of HIV-1 that associate with broadly neutralizing antibodies. PLoS Comput Biol (2010) 1.51
Beyond help: direct effector functions of human immunodeficiency virus type 1-specific CD4(+) T cells. J Virol (2004) 1.51
Epitope-dependent avidity thresholds for cytotoxic T-lymphocyte clearance of virus-infected cells. J Virol (2007) 1.48
Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol (2002) 1.44
Loss of the N-linked glycosylation site at position 386 in the HIV envelope V4 region enhances macrophage tropism and is associated with dementia. Virology (2007) 1.43
Relationship between functional profile of HIV-1 specific CD8 T cells and epitope variability with the selection of escape mutants in acute HIV-1 infection. PLoS Pathog (2011) 1.42
Parallel human immunodeficiency virus type 1-specific CD8+ T-lymphocyte responses in blood and mucosa during chronic infection. J Virol (2005) 1.41
The theta-defensin, retrocyclin, inhibits HIV-1 entry. AIDS Res Hum Retroviruses (2003) 1.40
Clinical efficacy of gene-modified stem cells in adenosine deaminase-deficient immunodeficiency. J Clin Invest (2017) 1.39
Persistent abnormalities in lymphoid tissues of human immunodeficiency virus-infected patients successfully treated with highly active antiretroviral therapy. J Infect Dis (2002) 1.38
Telomerase-based pharmacologic enhancement of antiviral function of human CD8+ T lymphocytes. J Immunol (2008) 1.34
Association study of common genetic variants and HIV-1 acquisition in 6,300 infected cases and 7,200 controls. PLoS Pathog (2013) 1.33
Clade-specific differences between human immunodeficiency virus type 1 clades B and C: diversity and correlations in C3-V4 regions of gp120. J Virol (2006) 1.30
Web-based design and evaluation of T-cell vaccine candidates. Bioinformatics (2008) 1.30
Immune failure in the absence of profound CD4+ T-lymphocyte depletion in simian immunodeficiency virus-infected rapid progressor macaques. J Virol (2004) 1.25
Evaluation of a tetraplex microsphere assay for Bordetella pertussis antibodies. Clin Vaccine Immunol (2006) 1.24
Antigenicity and immunogenicity of transmitted/founder, consensus, and chronic envelope glycoproteins of human immunodeficiency virus type 1. J Virol (2013) 1.24
Host genetic profiles predict virological and immunological control of HIV-1 infection in adolescents. AIDS (2002) 1.24
A novel variant marking HLA-DP expression levels predicts recovery from hepatitis B virus infection. J Virol (2012) 1.24
Los alamos hepatitis C immunology database. Appl Bioinformatics (2005) 1.23
Biomimetic enzyme nanocomplexes and their use as antidotes and preventive measures for alcohol intoxication. Nat Nanotechnol (2013) 1.23
The dual impact of HIV-1 infection and aging on naïve CD4 T-cells: additive and distinct patterns of impairment. PLoS One (2011) 1.23
Evolution of hepatitis C viral quasispecies after liver transplantation. Gastroenterology (2002) 1.18
Coping with viral diversity in HIV vaccine design: a response to Nickle et al. PLoS Comput Biol (2008) 1.17
A biochemical fluorometric method for assessing the oxidative properties of HDL. J Lipid Res (2011) 1.17
HIV-1 adapts to a retrocyclin with cationic amino acid substitutions that reduce fusion efficiency of gp41. J Immunol (2006) 1.17
Impacts of epitope expression kinetics and class I downregulation on the antiviral activity of human immunodeficiency virus type 1-specific cytotoxic T lymphocytes. J Virol (2004) 1.17
Increased sequence diversity coverage improves detection of HIV-specific T cell responses. J Immunol (2007) 1.17
Mycobacterium tuberculosis--heterogeneity revealed through whole genome sequencing. Tuberculosis (Edinb) (2012) 1.17
Human APOBEC3G-mediated editing can promote HIV-1 sequence diversification and accelerate adaptation to selective pressure. J Virol (2010) 1.15
In vivo suppression of HIV by antigen specific T cells derived from engineered hematopoietic stem cells. PLoS Pathog (2012) 1.14
Association between maternal and infant class I and II HLA alleles and of their concordance with the risk of perinatal HIV type 1 transmission. AIDS Res Hum Retroviruses (2002) 1.14
Persistence of dual-tropic HIV-1 in an individual homozygous for the CCR5 Delta 32 allele. Lancet (2002) 1.10